Tyrosine kinase inhibitors

Results: 62



#Item
1SUPPLEMENTARY	
  INFORMATION:	
  Specificity	
  and	
  mechanism-­‐ of-­‐action	
  of	
  the	
  JAK2	
  tyrosine	
  kinase	
  inhibitors	
  ruxolitinib	
  and	
   SAR302503	
  (TG101348)	
   1. Deter

SUPPLEMENTARY  INFORMATION:  Specificity  and  mechanism-­‐ of-­‐action  of  the  JAK2  tyrosine  kinase  inhibitors  ruxolitinib  and   SAR302503  (TG101348)   1. Deter

Add to Reading List

Source URL: www.biochem-caflisch.uzh.ch

- Date: 2014-03-12 10:03:01
    2CME  A Look at the Near Future of Lung Cancer Treatment Dates of certification: May 31, 2016, to May 31, 2017 Medium: Print with online posttest, evaluation, and request for credit

    CME A Look at the Near Future of Lung Cancer Treatment Dates of certification: May 31, 2016, to May 31, 2017 Medium: Print with online posttest, evaluation, and request for credit

    Add to Reading List

    Source URL: gotoper-com.s3.amazonaws.com

    Language: English - Date: 2016-06-03 12:14:22
    3Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

    Add to Reading List

    Source URL: www.pmda.go.jp

    Language: English - Date: 2016-08-04 23:26:42
    4ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

    ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

    Add to Reading List

    Source URL: www.zailaboratory.com

    Language: English - Date: 2015-11-24 01:50:17
    5TECHNOLOGY OFFER  A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent

    TECHNOLOGY OFFER A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent

    Add to Reading List

    Source URL: techtransfer.univie.ac.at

    Language: English - Date: 2015-07-01 06:41:06
    6MuTaLig COST ACTION CA15135 st 1 Annual meeting 2016 USI Lugano(CH), JulyPoster list

    MuTaLig COST ACTION CA15135 st 1 Annual meeting 2016 USI Lugano(CH), JulyPoster list

    Add to Reading List

    Source URL: www.mutalig.eu

    Language: English - Date: 2016-07-12 08:10:41
    7Blood Testing for EML4-ALK Fusion Transcripts in Non-Small Cell Lung Cancer Patients by ddPCR: A CLIA Lab Experience Hestia Mellert, PhD  April 17th, 2016

    Blood Testing for EML4-ALK Fusion Transcripts in Non-Small Cell Lung Cancer Patients by ddPCR: A CLIA Lab Experience Hestia Mellert, PhD April 17th, 2016

    Add to Reading List

    Source URL: www.biodesix.com

    Language: English - Date: 2016-05-02 01:40:22
    8Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

    Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

    Add to Reading List

    Source URL: www.biochem-caflisch.uzh.ch

    Language: English - Date: 2015-03-30 11:57:31
    9Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

    Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

    Add to Reading List

    Source URL: www.switt.ch

    Language: English - Date: 2014-02-01 16:41:28
    10Yuditiya P_Cell-Free mRNA Concentration of Plasminogen Activator Inhibitor-1...

    Yuditiya P_Cell-Free mRNA Concentration of Plasminogen Activator Inhibitor-1...

    Add to Reading List

    Source URL: repository.ui.ac.id

    Language: English